Form 4: Dianthus CFO Ryan Savitz Granted 60,000 Stock Options

Dianthus Therapeutics' CFO & CBO, Ryan Savitz, was granted 60,000 stock options with an exercise price of $37.87, vesting over four years.

Summary

• Ryan Savitz, CFO & CBO of Dianthus Therapeutics, Inc. (DNTH), was granted 60,000 stock options on September 23, 2025.
• The options have an exercise price of $37.87 per share.
• These options will vest in equal monthly installments over four years, starting from September 23, 2025, contingent on Mr. Savitz's continued service.
• The options are exercisable until their expiration date of September 23, 2035.
• Following this transaction, Mr. Savitz beneficially owns 60,000 derivative securities.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal for executive retention and alignment with shareholder interests, though it's a routine compensation event rather than a performance indicator.

Positives

• The grant of 60,000 stock options to a key executive, Ryan Savitz, aligns his interests with long-term shareholder value creation.
• A four-year vesting schedule encourages sustained commitment and performance from the executive.
• The options have a 10-year expiration date, providing a substantial window for potential value realization.

Negatives

• The executive receives no immediate cash benefit, as these are options, not shares, and their value is contingent on future stock price performance.
• The ultimate value of the options is dependent on the company's stock price exceeding the exercise price of $37.87.

Risks

• The value of the stock options is subject to market fluctuations and the company's future operational and financial performance.
• If the company's stock price does not rise above the exercise price of $37.87, the options may expire worthless.
• Vesting is contingent on continued service, meaning unvested options could be forfeited if Mr. Savitz's employment ceases.

Future Outlook

The grant of stock options to a key executive suggests a long-term commitment to the company's future growth and performance, as the options' value is directly tied to future stock price appreciation.

Industry Context

Executive equity grants are a standard practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize key talent, aligning their interests with long-term shareholder value creation and company success.

Comparison to Industry Standards

• The grant of 60,000 stock options to a CFO/CBO is a common form of executive compensation in growth-oriented biotech companies like Dianthus Therapeutics, comparable to practices at emerging biopharma firms.
• A 4-year vesting schedule is typical for executive equity awards, similar to practices seen at companies such as Moderna or BioNTech during their growth phases, aiming to retain talent and incentivize sustained performance.
• An exercise price equal to the market price on the grant date (implied by the nature of the grant) is standard for incentive stock options, aligning with common industry compensation structures.

Stakeholder Impact

• Shareholders: Potential positive impact through increased executive alignment with long-term stock performance and value creation.
• Employees: May signal stability in executive leadership and a commitment to long-term incentives for key personnel.

Next Steps

• Ryan Savitz will continue to serve as CFO & CBO, with options vesting monthly over the next four years from September 23, 2025.
• The company's operational and financial performance will determine the ultimate value of these options for the executive and shareholders.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (stock option grant) and does not contain information that would fundamentally alter the investment thesis for Dianthus Therapeutics. It indicates continued executive alignment but provides no new operational or financial performance data to warrant a change in recommendation.

Keywords

Dianthus Therapeutics, DNTH, Stock Options, Executive Compensation, Ryan Savitz, CFO, CBO, SEC Form 4, Equity Grant